Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sugino Appointed President of Amgen Astellas
June 2, 2017
- New Ninlaro Production Facility in Ireland Breaks Ground
June 2, 2017
- Eisai, Broad Institute Ink New Deal on Malaria Medicine
June 2, 2017
- Sawai’s Upsher-Smith Acquisition Completed
June 2, 2017
- PeptiDream, Shionogi, Sekisui Chemical to Form CMO for Specialty Peptide
June 2, 2017
- Once-Every-4-Week Administration of Praluent Meets Primary Endpoint in PIII Study in Japanese Patients: Sanofi
June 2, 2017
- FY2016 Earnings Roundup - 5: Drug Makers Anticipate Nearly Flat Growth in FY2017; Mid-Term Outlook Unclear
June 2, 2017
- Ono Licenses MEK Inhibitor, BRAF Inhibitor from Array Biopharma
June 1, 2017
- NBI, Kobe Univ. Tie Up to Develop Novel Treatments for Insulin-Resistant Disorders
June 1, 2017
- Daiichi Sankyo to Commercialize Opioid Analgesic in US, Eying Launch during FY2017
June 1, 2017
- FY2016 Earnings Roundup - 4: Average Productivity per Sales Rep Up Only 14 Million Yen in 6 Years
June 1, 2017
- FY2016 Earnings Roundup - 3: Price Battle Batters Generic Makers, 3 Majors’ Profit Rate in Single-Digits
May 31, 2017
- FY2016 Earnings Roundup - 2: Entyvio Robust, Xtandi Treads Water as Global Brands Underpin Revenue
May 30, 2017
- Sunovion’s COPD Med Slapped with FDA Complete Response Letter
May 30, 2017
- Sumitomo Dainippon to Adopt IFRS
May 30, 2017
- Bayer Fails to Report 12 Side Effect Cases for Xarelto, Scandal Probe Finds
May 29, 2017
- Zytiga Filed for Earlier Prostate Cancer Treatment
May 29, 2017
- FY2016 Earnings Roundup - 1: Japan’s Growth Potential Falters Despite 2.2% CAGR from FY2010
May 29, 2017
- Teijin Pharma Licenses Tau-Targeting Alzheimer’s Drug to Merck
May 29, 2017
- Over 50% of Doctors Don’t Allow Gx Switches for Certain Products: Survey
May 26, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…